To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.

By F. Danhier, Olivier Féron, V. Préat. Journal of Controlled Release, 2010

2,572 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/617ef03ce3e5cb35a8957fc797dc572deffe273f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Molecular Biology

Citations in the corpus

Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers (2012, neutral): “Tumor cells exhibit leaky vasculature due to incomplete angiogenesis.(53) Nanoparticles enter tumor tissue through these pores, and due to the poor lymphatic drainage system of cancerous tissues are retained for longer periods of time than normal cells.”
PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “Adapted from [14].”
Insight into nanoparticle cellular uptake and intracellular targeting (2014, neutral): “A high expression of TfR is known for immature erythroid, placental tissue, rapidly dividing cells, and its expression is about 100-fold higher in cancer cells than the regular expression of normal cells [108], which makes TfR as one of the most attractive targets for cancer therapy by receptor-medi”
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review (2018, background): “A smart drug delivery system utilizes two types of targeting: passive targeting and active targeting [168,169].”
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “, macrophages, fibroblasts) that can acquire a tumor survivalpromoting phenotype in response to cytokines in the tumor microenvironment (Coimbra et al., 2010; Danhier et al., 2010; Kuijpers et al., 2010; Danhier, 2016).”
Current trends in the use of liposomes for tumor targeting (2013, methodology): “EGF is overexpressed in many solid tumors, including colorectal, non-small-cell lung cancer, squamous cell carcinoma of the ovary, kidney, head, pancreas, neck and prostate, and especially breast cancer, which makes it an attractive target for therapeutic drug delivery [17,52].”
Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation (2015, background): “In addition to EPR, bioconjugation of nanogels to targeting ligands allows directing them to specific receptors or molecules differentially overexpressed on the diseased cells/tissues thus improving their retention at the targeted site as well as facilitating their cellular uptake [74,75].”